Related Experiment Video
Updated: Jun 27, 2026
10:00
High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
Pilot study of recombinant human alpha-interferon for chronic type B hepatitis
Gastroenterology
|January 1, 1986
Summary
This study on recombinant, human alpha-interferon for chronic hepatitis B found higher doses caused more side effects without improving antiviral efficacy. Lower doses given longer may be more beneficial for hepatitis B treatment.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Chronic hepatitis B virus (HBV) infection remains a significant global health concern.
- Recombinant human alpha-interferon (IFN-α) has been explored as a therapeutic option for chronic HBV.
- Understanding dose-response relationships and side effect profiles is crucial for optimizing IFN-α therapy.
Purpose of the Study:
- To evaluate the preliminary efficacy and safety of recombinant, human alpha-interferon in patients with chronic type B hepatitis.
- To assess the impact of different interferon doses on viral markers and clinical outcomes.
- To identify optimal dosing strategies for future hepatitis B treatment protocols.
Main Methods:
- A preliminary study involving nine patients with chronic type B hepatitis.
- Administration of recombinant, human alpha-interferon in one to four courses.
- Doses ranged from 18 to 100 million units, administered three times a week for two weeks.
- Monitoring of viral markers (HBV DNA polymerase, HBV DNA, HBeAg) and liver enzymes.
Main Results:
- Side effects (fever, fatigue, neutropenia) were dose-dependent and more severe at higher interferon doses (50 and 68 million units).
- Serum hepatitis B virus DNA polymerase activity decreased significantly during therapy across all doses but rebounded post-treatment.
- Two patients achieved sustained clinical remission, with clearance of HBV DNA, DNA polymerase, and HBeAg, and normalization of aminotransferase levels.
- One patient became hepatitis B surface antigen negative.
Conclusions:
- Higher doses of recombinant, human alpha-interferon (50 and 68 million units) exhibit greater toxicity without enhanced antiviral efficacy compared to lower doses (18 and 36 million units).
- Further research should focus on lower-dose interferon regimens administered over extended periods for chronic hepatitis B.
- Optimizing interferon therapy requires balancing efficacy with patient tolerability for improved hepatitis B management.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...